key: cord-1032278-gows1pyc
authors: Schaad, S.; Brahier, T.; Hartley, M.-A.; Cordonnier, J.-B.; Bosso, L.; Espejo, T.; Pantet, O.; Hugli, O.; Carron, P.-N.; Meuwly, J.-Y.; Boillat-Blanco, N.
title: Point-of-care lung ultrasonography for early identification of mild COVID-19: a prospective cohort of outpatients in a Swiss screening center
date: 2021-03-26
journal: nan
DOI: 10.1101/2021.03.23.21254150
sha: ef014c9bfcb5c7d50455363e333d28e02b3df314
doc_id: 1032278
cord_uid: gows1pyc

Background Early identification of SARS-CoV-2 infection is important to guide quarantine and reduce transmission. This study evaluates the diagnostic performance of lung ultrasound (LUS), an affordable, consumable-free point-of-care tool, for COVID-19 screening. Methods This prospective observational cohort included adults presenting with cough and/or dyspnea at a SARS-CoV-2 screening center of Lausanne University Hospital between March 31st and May 8th, 2020. Investigators recorded standardized LUS images and videos in 10 lung zones per subject. Two blinded independent experts reviewed LUS recording and classified abnormal findings according to pre-specified criteria to investigate their predictive value to diagnose SARS-CoV-2 infection according to PCR on nasopharyngeal swabs (COVIDpos vs COVIDneg). We finally combined LUS and clinical findings to derive a multivariate logistic regression diagnostic score. Results Of 134 included patients, 23% (n=30/134) were COVIDpos and 77% (n=103/134) were COVIDneg; 85%, (n=114/134) cases were previously healthy healthcare workers presenting within 2 to 5 days of symptom onset (IQR). Abnormal LUS findings were significantly more frequent in COVIDpos compared to COVIDneg (45% versus 26%, p=0.045) and mostly consisted of focal pathologic B-lines. Combining LUS findings in a multivariate logistic regression score had an area under the receiver-operating curve of 63.9% to detect COVID-19, but improved to 84.5% with the addition of clinical features. Conclusions COVIDpos patients are significantly more likely to have lung pathology by LUS. Our findings have potential diagnostic value for COVID-19 at the point of care. Combination of clinical and LUS features showed promising results, which need confirmation in a larger study population.

would allow immediate identification of infected patients at the point-of-care and be invaluable 81 to the sustainable control of the pandemic. Its diagnostic performance for pneumonia has been 82 established using chest CT as a gold standard [6] . For COVID-19, recent studies conducted in 83 emergency departments showed several LUS patterns ranging from mild interstitial infiltrate, 84 to lung consolidation, which correlated with disease progression and outcome [7, 8] . However, 85 these studies included mostly severe patients in emergency departments or intensive care units, 86

which may lead to overoptimistic diagnostic performance of LUS due to a spectrum effect [9] . 87

To our knowledge, no studies have described LUS findings in subjects with mild This study aims to compare LUS characteristics between SARS-CoV-2 PCR-confirmed 89 (COVID pos ) and PCR-negative (COVID neg ) patients in a screening center and explore LUS 90 performance for identification of COVID-19 outpatients. 91 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.23.21254150 doi: medRxiv preprint

This prospective cohort study recruited consecutive outpatients at the COVID-19 screening 94 center in Lausanne University Hospital, Switzerland (CHUV) between March 31 st and May 8 th 95 2020. All adults (age ≥ 18 years) presenting at the center with cough and/or dyspnea and who 96 fulfilled eligibility criteria for nasopharyngeal SARS-CoV-2 real time (Rt-) PCR according to 97

the State recommendations at the time of the study were eligible. These State criteria were the 98 presence of symptoms suggestive of COVID in a health worker or a subject with at least one 99 vulnerability criterion, i.e. age ≥ 65 years old or having at least one comorbidity (obesity, 100 diabetes, active cancer, chronic cardiovascular, pulmonary, liver, renal or inflammatory 101 disease). Exclusion criteria were uninterpretable Rt-PCR results or absence of LUS recording. 102

Written informed consent was obtained from all participants. 103

To ensure that LUS abnormal findings would be specific of a respiratory tract infection, we 104 included a control group of healthy volunteers, matched for age (+ 5 years), sex, and smoking 105 status with COVID pos patients (Supplementary Table 1 ). These volunteers were asymptomatic 106 during the previous 15 days (absence of odynophagia, cough, dyspnea, runny nose, fever, loss 107 of smell or taste) and did not have a documented SARS-CoV-2 infection. 108

At inclusion, demographics, comorbidities, symptoms (including duration), and vital signs were 109 collected using a standardized electronic case report form in REDCap® (Research Electronic 110 Data Capture). Patients were subsequently classified as either COVID pos or COVID neg 111 according to the SARS-CoV-2 RT-PCR results (at inclusion or at any time during the 30-day 112 follow-up if the test was repeated for the same clinical episode). We assessed 30-day outcome 113 by phone using a standardized interview (persistence of symptoms, secondary medical 114 consultation, hospital admission, death). 115 116 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Subjects were not involved in the design or conduct of this study. 120

The minimum sample size required for this study was 100 patients with a clinical suspicion of 122 COVID. It was calculated using a COVID prevalence of 20% and an estimated sensitivity of 123 LUS to identify COVID pos at 80% This sample size guarantees a power of 80% with a false 124 discovery rate of 5% [10]. 125

Three medical students trained in LUS performed image acquisitions in the triage site. The first 127 10 acquisitions were done under direct supervision of an experienced board-certified expert 128 (OP) who verified the quality of recorded images. Acquisition was standardized according to 129 the "10-zone method" [11, 12] , consisting of five zones per hemithorax. Two images (sagittal 130 and transverse) and 5 second videos were systematically recorded in every zone with a Butterfly 131 IQ TM personal US system (Butterfly, Guiford, CT, USA), using the lung preset. The LUS probe 132 and the electronic tablet were disinfected with an alcohol-based solution between each patient 133 to avoid nosocomial spread [13] . 134

For interpretation of LUS pathology, a physician experienced in LUS (TB) and an expert 135 radiologist (JYM), blinded to patients' diagnoses, independently filled a standardized report 136 form as previously described [8] . Discordance between the two readers were adjudicated by a 137 third expert (OP). The abnormal images were summed up in a LUS score for each patient, as 138 previously described [8, 14, 15] . 139

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

• Binary variables for the presence of cough, sputum, dyspnea, fever, anosmia, 153 rhinorrhea, myalgia, and diarrhea 154

• Continuous variables for temperature, oxygen saturation, and respiratory rate 156

• Binary variable for a history of known unprotected contact with a COVID-19 case 158

Feature coefficients are presented, as well as their importance in ranked order from RFE . 159

Performance at several stages of the RFE are reported, using the top 22, 15, 10 and 8 features. 160 Models using just LUS or just clinical findings were also built. 161

Diagnostic performance is reported as sensitivity, specificity, positive and negative predictive 162 values (PPV, NPV), positive and negative likelihood ratios (LR+, LR-) and area under the 163 receiver-operator curve (AUC). Due to the dataset size, we report findings on the entire dataset. 164 A diagnostic score was derived from the summed coefficients, normalized within a range from 165 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.23.21254150 doi: medRxiv preprint -6 (COVID pos highly unlikely) to +4 (COVID pos highly likely) and the number of patients in 166 each class are presented for each value of the score. The optimal cut-point was chosen using 167

Youden index [16] . 168

The kappa coefficient was calculated to measure the inter-rater agreement between the two LUS 169 readers. R Core Team (2019) statistical software and python 3.0 with the sklearn library was 170 used for analyses. Similar analyses were attempted on the outcome at 30-day follow up but 171 impossible due to the limited sample size. 172

The reporting of our results followed the STARD guidelines. 173 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 26, 2021.

A total of 141 patients met inclusion criteria and were enrolled into the study; eight (5%) were 176 later excluded, due to uninterpretable PCR results or LUS technical issues. Of the 134 177 remaining patients, 31 (23%) were classified as COVID pos and 103 (77%) as COVID neg based 178 on Rt-PCR test. Among the 13 COVID neg patients who had a second screening test during the 179 30-day follow-up, only one had a positive SARS-CoV-2 Rt-PCR, related to a clearly distinct 180 clinical episode. This patient was thus classified as COVID neg . Most patients were female 181 (63%), healthcare workers (85%) with a median age of 35 years; most sought out testing within 182 the first 5 days of symptom onset (Table 1 ). COVID pos patients had fewer comorbidities than 183 COVID neg , the latter suffering mostly from asthma, obesity or hypertension. COVID pos patients 184 presented more often with a history of fever and anosmia, but less often with dyspnea than 185 COVID neg patients. Vital signs at inclusion were normal in most patients of both groups. 186

Lung ultrasound was abnormal in 31% of patients ( Table 2) Table 2 ). 193

Among all symptomatic patients, two factors were significantly associated with abnormal LUS: 194 SARS-CoV-2 infection and history of fever (Table 3) . Indeed, COVID pos patients had abnormal 195 LUS findings significantly more frequently compared with COVID neg (45% versus 26%, 196 p=0.045). However, this feature alone was poorly sensitive (45%) and specific (74%). No 197 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.23.21254150 doi: medRxiv preprint specific ultrasonographic pattern on its own significantly distinguished COVID pos from 198 COVID neg subjects (Table 2) . 199

Although not statistically different, the proportion of COVID-19 pos with abnormal LUS 200 findings was positively associated with symptoms duration. While only 30% of COVID-19 pos 201 patients had abnormal LUS within 2 days of symptom onset, 52% of patients had pathological 202 LUS after 2 days (p=0.24). 203

We combined LUS findings with symptoms, vital signs and a binary feature for known contact 205 with a COVID-19 case to build a multivariate logistic regression diagnostic score. Using all 206 features, the score had 78.8% sensitivity, 84.0% specificity, 83.1% PPV, 61.4% NPV, 4.9 LR+, 207 0.3 LR-and 84.5% AUC (Figure 1 ). We present a plot on which to assess the score according 208 to a desired sensitivity/specificity trade-off. 209

In Table 4 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

The 30-day follow-up was available for 121/134 (90%) patients. None was hospitalized or died 226 during follow-up. COVID pos patients had more frequently persistent symptoms (fatigue, 227 dyspnea or anosmia) at 30-day compared with COVID neg (Table 1) . 228

The presence of an abnormal LUS at inclusion was not associated with symptom persistence 229 (Table 3) . 230

As no patients were admitted or died, we could not analyze the value of LUS findings to predict 231 critical clinical outcome. 232 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The clinical severity of the disease strongly affects the performance of diagnostic tests, and 253 particularly the sensitivity of LUS. We conclude that while LUS may be an interesting COVID-254 19 screening tool in emergency departments, it is not reliable when used alone in patients with 255 mild disease. In the only study investigating chest CT features in patients with asymptomatic 256 (73%) or mild (27%) COVID-19, which was conducted in the passengers of the cruise ship 257 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in We observed more abnormal LUS findings in COVID pos patients who had more than 2 days of 266 symptoms (52% versus 30%), although our results were not statistically significant. Concordant 267 with our findings, a relationship between the duration of infection and the proportion of 268 abnormal radiological findings has been described [22] [23] [24] . In one study, only 44% of patients 269 presenting within 2 days of symptoms had an abnormal CT, while this proportion rose to 91% 270 after 3 to 5 days and 96% after 5 days [24] . This study did not provide any data on COVID-19 271 severity. In another study using chest X-ray in patients admitted to the emergency department, 272 the proportion of an abnormal chest X ray increased with the duration of symptoms (63% in the 273 first 2 days to 84% after 9 days) [ To our knowledge, this is the first study, which assessed the use of LUS in a screening center 298 outpatient population with mild COVID-19. As disease severity plays an important role in the 299 ultrasonographic findings, LUS is poorly sensitive as a SARS-CoV-2 screening tool in the 300 context of mild community-level screening. However, the good performance of a combination 301 of clinical and LUS features showed promising results, which could be used to avoid a PCR 302 test in patients with a negative screening. These results need confirmation in a larger study 303 population. 304 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.23.21254150 doi: medRxiv preprint

Coronavirus Disease 2019 in China

Correlation of Chest CT and RT-330 PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 331 1014 Cases

Chest CT 333 Findings in Cases from the Cruise Ship "Diamond Princess

Radiological findings from 81 336 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Thoracic imaging tests for the diagnosis of COVID-19

Lung ultrasound in diagnosing pneumonia in the 342 emergency department: a systematic review and meta-analysis

Findings of lung ultrasonography of novel corona 345 virus pneumonia during the 2019-2020 epidemic

Lung ultrasonography for risk stratification in patients with COVID-19: a prospective 348 observational cohort study

Spectrum Bias or Spectrum Effect? Subgroup Variation in 351 Diagnostic Test Evaluation

Requirements for Minimum Sample Size for Sensitivity and 353 Specificity Analysis

Thoracic 355 Ultrasound: Technique, Applications, and Interpretation

International evidence-based recommendations for point-of-care lung ultrasound

Guidelines for Cleaning and Preparing External-and Internal-Use Ultrasound 361 Transducers and Equipment Between Patients as well as Safe Handling and Use of 362 Ultrasound Coupling Gel

Thoracic ultrasonography: a narrative review

Proposal for International Standardization of the Use of Lung Ultrasound for Patients With 367 COVID-19

Optimal cut-point and its 369 corresponding Youden Index to discriminate individuals using pooled blood samples

Lung Ultrasound Is More Sensitive than Chest Radiograph for Evaluation of COVID-19

The 375 association of lung ultrasound images with COVID-19 infection in an emergency room 376 cohort

The role of lung 378 ultrasound as a frontline diagnostic tool in the era of COVID-19 outbreak

Chest CT 381 and Coronavirus Disease (COVID-19): A Critical Review of the Literature to Date

Sensitivity of Chest CT for 384 COVID-19: Comparison to RT-PCR

COVID-19): A Systematic Review of Imaging Findings in 919 Patients

A rapid advice 389 guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected 390 pneumonia (standard version)

Chest CT Findings 392 in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection

Radiographic findings in 240 patients with COVID-19 pneumonia: time-dependence after the 396 onset of symptoms

Screening of 398 healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-399 19 transmission

Diagnostic 401 strategies for SARS-CoV-2 infection and interpretation of microbiological results

Comparison of SARS-CoV-2 RT-PCR on a 404 high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the 405 diagnostic of COVID-19 on various clinical samples

Follow-up at 30 days